Takeda Pharmaceutical Co Ltd ADR

Yahoo Finance • 2 months ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical... Full story

Yahoo Finance • 3 months ago

Vatroslav Mateljic Appointed General Manager of Takeda Canada

Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sector TORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Taked... Full story

Yahoo Finance • 6 months ago

Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts

The New Expanded Partnership Will Aim to Support the Dismantling of Systemic Barriers to Equity and Help Strengthen the Health Workforce in Massachusetts The Existing Global Partnership Has Provided Screening and Diagnostic Services to Ove... Full story

Yahoo Finance • 7 months ago

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

cTTP Is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 If Approved in the European Union, rADAMTS13 Will Be the First and Only Recombin... Full story

Yahoo Finance • 10 months ago

Japan's Takeda partners with India's Biological E. to boost dengue vaccine production

BENGALURU (Reuters) - Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday. These doses will be available for gov... Full story

Yahoo Finance • 10 months ago

11 Best Japanese Stocks To Buy In 2024

In this article, we discuss 11 best Japanese stocks to buy in 2024. If you want to skip our discussion on the Japanese economy, head over to 5 Best Japanese Stocks To Buy In 2024. Japan has effectively managed the challenges posed by the... Full story

Yahoo Finance • 10 months ago

20 Fastest Growing Biotech Companies in the US

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In Th... Full story

Yahoo Finance • 10 months ago

30 Most Valuable Drug Companies in 2024

In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global P... Full story

Yahoo Finance • 10 months ago

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial − TAK-861 Was Found to be Generally Safe and Well-Tolerated − Results Will be Presented at an Upcoming Scientific Congress OSAKA, Japan & CAMBRIDGE, Mass... Full story

Yahoo Finance • 11 months ago

Takeda Announces Chief Financial Officer Succession

OSAKA, Japan & CAMBRIDGE, Mass., February 01, 2024--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be cl... Full story

Yahoo Finance • 11 months ago

Takeda Pharmaceutical’s Third-Quarter Net Profit Dropped on Lower Margins

The Japanese drugmaker reported a drop in third-quarter net profit due partly to lower margins despite some growth in revenue. Continue reading... Full story

Yahoo Finance • 11 months ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's InvestigationalInjectable Hepcidin Mimetic Currentl... Full story

Yahoo Finance • last year

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards OSAKA, Japan & CAMBRIDGE, Mass., December 05... Full story

Yahoo Finance • last year

Hong Kong Shares Fall as Alibaba Slides

Hong Kong equities were lower in early trading, dragged by tepid sentiment in U.S. markets and a selloff in Alibaba. Continue reading... Full story

Yahoo Finance • last year

Takeda Pharmaceutical Books Second-Quarter Net Loss

Takeda Pharmaceutical reported a second-quarter net loss due to impairment losses on certain products and cut its net-profit forecast for the fiscal year ending March 2024. Continue reading... Full story

Yahoo Finance • last year

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited — Third major market authorization application based on data from the FRESCO-2 global Phase III trial — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li... Full story

Yahoo Finance • last year

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS). Both companies offer attractive dividends, but which one is a be... Full story

Yahoo Finance • last year

UPDATE 1-Takeda withdraws US application for dengue vaccine candidate

(Adds details on vaccine throughout, background on Sanofi's dengue vaccine in paragraph 4) July 11 (Reuters) - Takeda Pharmaceutical Co said on Tuesday it was voluntarily withdrawing its application for its dengue vaccine candidate, follo... Full story

Yahoo Finance • last year

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Data from First and Only Phase 3 Controlled Trial in cTTP Demonstrate Strong Efficacy and Favorable Safety Profile with TAK-755 (recombinant ADAMTS13), Compared to Plasma-Based Therapies Patients Receiving TAK-755 Achieved an Increase in P... Full story

Yahoo Finance • 2 years ago

ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity

The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients in the U.S. who have been facing a na... Full story